Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Foreign Price Adjustment Rule to Be Toughened
February 6, 2006
- JPMA Announces GL on Licensing of Patents on Research Tools
February 6, 2006
- 21 New Drugs Approved
February 6, 2006
- R&D NEWS IN BRIEF
February 6, 2006
- Atypical Antipsychotic Abilify: Otsuka
February 6, 2006
- Proposed Revision of Medical Materials System Approved by Chuikyo
February 6, 2006
- Silodosin to Improve Dysuria: Kissei
February 6, 2006
- MEDICAL DEVICE NEWS IN BRIEF
February 6, 2006
- Femara for Breast Cancer: Novartis
February 6, 2006
- JSMI to Submit Petition on Self-medication to Korosho
February 6, 2006
- 3 Drugs, 1 Diagnostic Recommended for Approval
February 6, 2006
- Group of Pharmacy Chains Calls For Sale of Drugs via Internet
February 6, 2006
- Toyama, Nidek Granted Approval for Tosufloxacin Eye Drops
February 6, 2006
- Sysmex to Shift Focus to Disease Management
February 6, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 6, 2006
- Serono Japan Granted Approval for Follitropin a to Treat MHH
February 6, 2006
- Eisai to Establish European Strategic Hub in the UK
February 6, 2006
- Lead Chemical, Sankyo Announce Approval of Loxonin Poultice
February 6, 2006
- Takeda's Future Depends on Its Drug Discovery Research: Mr Takeda
February 6, 2006
- Obsessive Compulsive Disorders Approved as New Indication for Paxil: GSK
February 6, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…